What is Scilogica?
Scilogica is dedicated to enhancing patient outcomes and reducing hospital expenditures through its proprietary Elucido platform. This technology offers real-time, precise measurement of blood analytes, enabling critical monitoring for critically ill patients. The company's strategy involves integrating its platform with various extracorporeal blood treatment systems to facilitate rapid, life-saving decisions informed by immediate data. Scilogica's team is adept at collaborating with healthcare providers to tailor solutions for optimal clinical impact. The Elucido platform is currently undergoing development and is slated for regulatory submission.
How much funding has Scilogica raised?
Scilogica has raised a total of $62K across 1 funding round:
Debt
$62K
Debt (2021): $62K with participation from PPP
What's next for Scilogica?
With significant backing at a Series B/C stage, Scilogica is poised for accelerated growth and market penetration. The substantial expansion capital is expected to fuel further development of the Elucido platform, streamline regulatory processes, and scale commercialization efforts. This strategic investment underscores confidence in Scilogica's mission to revolutionize critical care by providing real-time physiological insights, potentially setting new standards in patient monitoring and intervention.
See full Scilogica company page
